2 active not recruiting, 2 completed, 2 recruiting, 1 unknown. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 2, Completed 2, Recruiting 2, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow pralsetinib: new trials by email Literature Review of pralsetinib trials Research Report on pralsetinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. Sunvozertinib, Crizotinib, Pralsetinib - Lung Cancer Stage III, Mutation | Phase 2 | Recruiting | Sun Yat-sen University | 120 | 2024-11-01 | 2026-04-21 |
| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer Anlotinib, Lenvatinib, Sorafenib - Locally Advanced Thyroid Gland Carcinoma | Phase 2 | Recruiting | West China Hospital | 75 | 2021-06-01 | 2024-12-05 |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Entrectinib, Alectinib, Atezolizumab - Solid Tumors | Phase 2 | Active not recruiting | Hoffmann-La Roche | 920 | 2021-01-18 | 2026-09-04 |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Entrectinib, Inavolisib, Alectinib - Advanced Unresectable or Metastatic Solid Malignancy | Phase 2 | Completed | Genentech, Inc. | 252 | 2021-01-13 | 2025-01-08 |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) Alectinib, Entrectinib, Vemurafenib - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Genentech, Inc. | 99 | 2020-11-06 | 2026-11-10 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
Carcinoma, Non-Small-Cell Lung (4) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma, Papillary (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Medullary (1) · Carcinoma, Neuroendocrine (1) · Colonic Diseases (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1)
Genentech, Inc. (2) · Hoffmann-La Roche (2) · Fondazione per la Medicina Personalizzata (1) · Sun Yat-sen University (1) · West China Hospital (1)
China (4) · United States (4) · Italy (3) · Belgium (2) · France (2) · Germany (2) · Hong Kong (2) · Singapore (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Canada (1)
Andrea Botticelli (1) · Paolo Marchetti (1) · Si-Yu Wang, MD (1) · Zhihui Li, Professor (1)
PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40086048, PMID 40304938, PMID 40639400, PMID 41023484, PMID 41213248, PMID 41392942, PMID 41886723, PMID 41963505
2016 (1), 2018 (1), 2023 (1)